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Adherence is the first and one of the most important steps of bacterial
pathogenesis. Natural derived components that inhibit the adherence of
pathogens to the surface of epithelial cells have received considered interest.
The goal of this research was to assess the anti-adherence activity of mannan
oligosaccharides (MOS), pectic oligosaccharides (POS) and cranberry high
molecular weight component (HMW) against Campylobacter jejuni and
Campylobacter coli. First the anti-adherence activity of MOS and their purified
fraction (pMOS) was tested against three strains of C. jejuni and two strains of C.
coli. Results shown significant reductions in adherence (up to 70%) of all C. jejuni
strains and for C. coli ATCC 43485 in presence of MOS or pMOS (50 mg/mL).
The mannan oligosaccharide fraction appear to be the responsible for the antiadherence activity of MOS. Adherence inhibition (up to 70%) was also observed!

in presence of HMW at the highest concentration of 5 mg/mL of all the strains
except for C. coli ATCC BAA-1061. Additionally, a blend of MOS-HMW did not
shown additive effect to inhibit the adherence of all five Campylobacter strains.
POS was not effective to inhibit the adherence of any of the strains tested in this
study.

Invasion inhibition was not observed in the presence of any of the

components tested. These results show that naturally derived molecules as MOS
and HMW can be used for animal production to reduce pathogens colonization
and prevent the onset of human infection.
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Preface

This thesis is compromised of five chapters. Chapter 1 provides a review of the
current literature on the anti-adherence effect of different non-digestible
oligosaccharides and plant extracts. Chapter 2 provides a review of the uses of
mannan oligosaccharides as animal feed supplement. Chapter 3 describes a
study on the effect of Mannan oligosaccharides and Cranberry high molecular
weight component on the adherence of Campylobacter jejuni and Campylobacter
coli in HEp-2 cells. Chapter 4 describes the results of testing pectin
oligosaccharides as anti-adherence agents against Campylobacter jejuni and
Campylobacter coli to HEp-2 cells. Finally, Chapter 5 provides a conclusion
session that summarizes the major research findings presented within this thesis.
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Non-digestible oligosaccharides as anti-adherence agents against enteric
pathogens

!

!

2!

Introduction
Non-digestible oligosaccharides (NDO) have received much recent
research

and

commercial

attention

due

to

their

important

functional,

physiological, and biological properties. In particular, some NDOs have the ability
to modulate the intestinal microbiota by enriching for health-promoting bacteria.
In addition, NDO may also interfere with the ability of enteric pathogens to
colonize the intestinal tract (Paeschke & Aimutis, 2011).
Many commercial NDO are either found naturally or are derived from
plant materials. Others are obtained from microbial sources, including fungi. In
addition,

shellfish

and

milk

can

also

serve

as

a

source

of

NDO.

Galactooligosaccharides (GOS), fructooligosaccharides (FOS) and inulin are well
studied NDOs that has been recognized for their prebiotic properties. Anew class
of NDOs that have gained interest in the past years are derived from plant cell
wall polysaccharides. Similar hydrolysis processes are used to obtain
oligosaccharides

from

oligosaccharides

can

these
be

sources.

made

from

For

example,

soybeans

and

arabinogalactosugar

beets,

rhamnogalacturono-oligosaccharides from apple, mannan-oligosaccharide from
yeast, xylo-oligosaccharides from bamboo shoots, pectic oligosaccharides from
orange pectin (Mussatto & Mancilha, 2007; Voragen, 1998).
Several of these oligosaccharides are derived from waste materials
resulting from food processing and other of manufacturing industries. There is
much interest in these products due to their low raw material cost and potential
bioactive properties. This interest has led to development of new technologies for

!

!

3!

extraction and purification of NDOs, as well as studies to analyze their structural
and function properties.
In this review, the composition and structure of several important NDOs
and their biological properties will be presented. The primary focus will be on the
ability of NDO to reduce adherence of enteric pathogens, especially
Campylobacter, one of the leading causes of gastroenteritis in the U.S.

Physical-chemical properties of non-digestible oligosaccharides
Non-digestible oligosaccharides (NDOs) are defined as carbohydrates that
are not digested (or minimally digested) in the stomach or small intestine and
arrive in the large intestine mostly intact, where they might then be utilized by gut
microbiota (Paeschke & Aimutis, 2011). This concept was based, in part, on the
observation that the anomeric carbon atom (C1 to C2) of monosaccharide units
of some dietary oligosaccharides has a configuration that makes their osidic
bounds (also called glycosidic linkages) non-digestible to the hydrolytic activity of
the human digestive enzymes (Mussatto & Mancilha, 2007; Roberfroid & Slavin,
2000). NDOs are made from one, two or even three different types of
monosaccharides (Crittenden & Playner, 1996). They are generally low
molecular weight carbohydrates, containing sugar moieties with degrees of
polymerization (DP) between 3 and 10. (Patel & Goyal, 2011;Weijers et al., 2008)
and water soluble usually between 0.3-0.6 times as sweet sucrose.
NDOs are widely found in nature and are common constituents of many
foods such as milk, honey, fruits and vegetables (i.e. onion, Jerusalem artichoke,
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chicory, leek, garlic, artichoke, banana, rye, barley) (Crittenden & Playner, 1996;
Mussatto & Mancilha, 2007). These naturally-derived components are produced
by hydrolyzing polysaccharides or by enzymatic and chemical synthesis from
disaccharide substrates (Mussatto & Mancilha, 2007; Sako et al., 1999) (Table
2).
NDOs have been associated with many health benefits, including positive
effects on fermentation, mineral absorption, barrier function, fat metabolism,
glycemic and insulin responses (Meyer, 2004; Nauta & Garssen, 2013). Hence,
they have been introduced as functional food ingredients (Mussatto & Mancilha,
2007; Van Loo et al., 1999).

The Campylobacter problem
Campylobacter infection is a leading cause of human bacterial
gastroenteritis in the United States, with more than 1.3 million campylobacteriosis
cases reported in 2012 (CDC, 2013a). Poultry has been identified as a major
reservoir for this pathogen, and contaminated broiler chicken meat is believed to
be responsible for 50 - 70% of the human Campylobacter cases (EFSA, 2010;
Hermans et al., 2011). Indeed, chickens are commonly colonized by
Campylobacter jejuni, with prevalence rates of 60-80% (EFSA, 2010). Therefore,
strategies to prevent Campylobacter colonization in chicken are a high priority.

!
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Epidemiology
Campylobacter spp. are commonly found as commensals in the

gastrointestinal tract of wild or domesticated cattle, sheep, swine, goat, dogs,
cats, and all classes of poultry; (Lee & Newell, 2006; Stanley & Jones, 2003). C.
jejuni is predominantly associated with poultry (EFSA, 2004; FAO/WHO, 2009;
Tauxe et al.,1992) and C. coli is found at higher prevalence in pigs (EFSA, 2004;
Nielsen et al., 1997; Rosef et al., 1983). The handling and consumption of poultry
meat is considered a significant risk for human infection (Corry & Atabay, 2001;
Ganan et al., 2009).
The

most

important

foodborne

species

of

Campylobacter

are

Campylobacter jejuni and Campylobacter coli. Together, they account for over
95% of Campylobacter infections in humans (Park, 2002). Surveys have
suggested that in the U.S., nearly 70% of chicken carcasses processed on-farm
are contaminated with Campylobacter (Timble et al., 2013).

These authors

reported that in the slaughter facility this number increased to 82%. The
Foodborne Disease Active Surveillance Network (FoodNet) found a 30% decline
in the rates of infection in 2009 for Campylobacter compared with previous years.
However, low level of contamination is a public health risk, since the reported
infectious dose for this pathogen is less than 500 CFU (Black et al., 1988; Park,
2002).
Moreover, it is generally assumed that C. jejuni and C. coli do not multiply
during slaughter, post-processing, transport and refrigeration storage of chicken
products, since they require high growth temperature of around 42°C

!
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(FAO/WHO, 2009). However, Campylobacter spp. can persist for long times in
chilled and frozen products. Proper cooking is sufficient to inactivate
Campylobacter as they are sensitive to heat (FAO/WHO, 2009; ICMSF, 1996).

Campylobacteriosis
In many industrialized nations, Campylobacter jejuni is the most frequently
identified pathogen associated with acute diarrheal disease (Acheson & Allos,
2001). Campylobacter infections usually involve sporadic cases, or as part of
small, family-related outbreaks (FAO/WHO, 2009). The infection due to
Campylobacter is called campylobacteriosis and are most prevalence in children,
elderly people and patients with compromised immune system (Wassenaar &
Blaser, 1999; Young et al., 2007). Any individual who has consumed the
organism from contaminated food or water is at risk of develop the disease
(Altekruse et al., 1999). However, campylobacteriosis is a self-limited disease,
and most patients recover almost completely after 1 week (Dasti et al., 2010).
In developing countries, Campylobacter species are an important cause of
childhood morbidity caused by watery diarrhea predominantly (Acheson & Allos,
2001). In developed countries, campylobacteriosis manifests as bloody diarrhea
with mucus, and is usually self-limiting (Young et al., 2007). Although 14 species
of Campylobacter have been identified, in the United States, more than 99% of
reported infections with Campylobacter are with C. jejuni (Buzby et al., 1997;
Friedman et al., 2000). Approximately 0.1% of C. jejuni cases are associated with
serious ascending motor neuron paralytic disease Guillain-Barré syndrome
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(Mandrell et al., 2005; Nachamkin et al., 1998). Studies have reported that 20%
to 40% of patients with Guillain-Barré syndrome (GBS) have evidence of recent
Campylobacter jejuni infection (Buzby et al., 1997; CDC, 2013b), in the 1-3
weeks prior to the onset of neurologic symptoms (Rees et al., 1995). Ang et al.,
2004 have suggested that C. jejuni probably triggers the GBS through molecular
mimicry between core lipooligosaccharides (LOS) in the bacterial cell wall and
gangliosides in human peripheral nerve tissue as a consequence cause the
paralysis.
Worldwide, the economic loss due to C. jejuni infection has been
estimated to be in excess of US$ 2 billion per year (CDC, 2013b). Adding to the
human and economic costs of C. jejuni are the chronic sequelae associated with
this infection (Altekruse et al., 1999). In 2012, the Foodborne Diseases Active
Surveillance Network (FoodNet) estimated the incidence to be 14.3 cases per
100,000 populations. An estimated 1.3 million persons are affected each year
(CDC, 2013b).
Campylobacter and antibiotics
Antibiotics are commonly given to chickens to promote growth by
increasing weight gain, improving feed efficiencies, reducing mortality, and
inhibiting pathogens colonization (Gaskins el al., 2002; Phillips et al., 2004).
However, the emergence of antibiotic resistant Campylobacter strains has
significantly increased in the recent years (Rautelin et al., 1991; White et al.,
2002). In 2006, the European Union banned the use of antibiotics in animal feed.
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Hence, alternative approaches to reduce Campylobacter colonization in livestock
animals are required.
Resistance of Campylobacter to many common antibiotics, including
ampicillin,

streptomycin,

tetracycline,

erythromycin,

gentamycin,

and

fluoroquinolones has been reported (Adzitey et al., 2012; Nobile, et al., 2013).
Fluoroquinolone-resistance has especially concerned public health authorities,
because this antibiotic is commonly used as first-line therapy for urinary tract
infection, enteric infection and gonococcal infection (Cheng et al., 2012;
Redgrave et al., 2014). It has been proposed that this resistance is due, in part,
for the use of fluoroquinolones to control mortality associated with Escherichia
coli infection (McDermott et al., 2002), and also to treat colibacilllus and
Mycoplasma infections in poultry (Wagenaar et al., 2006), as a side effect, the
Campylobacter spp present in the gastrointestinal tract of the bird become
resistance.
Usui et al., 2014 reported that treatment of pigs with fluoroquinolones
select to fluoroquinolones-resistance Campylobacter and persist in the GIT after
the treatment for up to 21 days, becoming a significant risk of potential
contamination in humans.

Virulence mechanisms.
The mechanisms of pathogenesis for Campylobacter are not well
understood. Several proteins have been identified to play an important role in the
adherence mechanism of C. jejuni (Fouts et al., 2005; Parkhill et al., 2000; Young

!
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et al., 2007). CadF is an outer membrane protein that binds specifically to
fibronection, which is located on epithelial cells (Konkel et al., 1999) and it is
expressed by all C. jejuni and C. coli strains (Dasti et al., 2010). Previous studies
have shown that cadF mutants had significantly reduced capacity to colonize
poultry compared with the wild type strain (Monteville et al., 2003; Young et al.,
2007; Ziprin et al., 1999).

CapA (Campylobacter adhesin protein A), JIpA

(Campylobacter jejuni surface lipoprotein A), PEB1 (periplasmic binding protein)
have been identified and suggested to mediate adherence of the bacterium to
epithelial cells (Flanagan et al., 2009; Jin et al., 2003; Pei et al., 1998).
Additionally, other proteins have been described (Cj1270c and Cj1349) to contain
Fn type III domains and act as an Fn and fibrinogen-binding protein (Flanagan et
al., 2009).
The ability of C. jejuni and C. coli to become established in the
gastrointestinal tract of chickens is thought to involve binding and colonization of
the intestinal cell surface (Ganan, et al., 2009; Park, 2002). The mechanisms by
which Campylobacter spp. induce disease in humans is not well understood, but
there are some mechanisms postulated for gastrointestinal disease that involve
bacterial adherence, invasion and colonization of the intestinal mucosa (Park,
2002). The study of Campylobacter pathogenesis is limited by a lack of
understanding of the physiology and virulence factors. Hence, in vivo and in vitro
models with live animals and tissue culture cells have been used as a suitable
alternative to understand the interactions between Campylobacter and the host
epithelium cells.

!
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Adherence
Adherence is the first, and one of the most important steps in bacterial
pathogenesis (Savage, 1977; Shoaf et al., 2009). Indeed, pathogens that have
lost their ability to adhere generally become avirulent (Casadevall & Pirofski,
2001). At a molecular level, adherence is a receptor-mediated process between
lectin-like bacterial adhesins and their complementary ligands located on the
mucosa surface (Finlay & Falkow, 1989a; Pieters, 2011).

Most bacterial

adhesins are organized as thin thread-like organelles called fimbriae or pili
(Klemm et al., 2010). Importantly, adhesins can be highly specific. Ultimately,
the specificity of a bacterial pathogen for a particular host or host tissue depends
on the presence of definitive oligosaccharide receptors (Firon et al., 1984; Shoaf
et al., 2006). Any specific receptor may contain more than one attachment site
for two or more bacterial adhesins (Ofek et al., 2003). Additionally, two different
pathogens can express distinct adhesins that have the same receptor specificity
(Ofek et al., 2003; Wilson, 2002).
Studies on the bacterial adhesion-host receptor interaction have led
researchers to suggest possible strategies to prevent pathogen colonization by
blocking the adhesin-receptor interference. Thus, agents that inhibit adherence
of foodborne pathogens to the surface of cells have attracted considerable
attention in the past years (Shoaf & Hutkins, 2008).
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Anti-Adherence
The anti-adherence model is based in the observation of the interaction
between bacterial adhesins and host receptors located at the surface of host cell
(Klemm et al., 2010b). One of the anti-adhesive mechanisms that have been
studied is based on the structural similarity that non-digestible oligosaccharides
have to intestinal cell surface receptors (Kunz et al., 2000). Hence, acting as
receptor analogs or decoys that result in blocking the adherence process (Shoaf
et al., 2008) (Figure 1). As a consequence, pathogens bind to the
oligosaccharide decoys and are displaced from the intestinal tract, preventing the
onset of infection (Shoaf & Hutkins, 2009). There is significant evidence that
supports the use of non-digestible oligosaccharides from natural resources (e.g.
human milk oligosaccharides and xyloglucan from berries) and synthetics (e.g.
galactooligosaccharides, N-acetyl-galactosamine, chitooligosaccharides) act as
molecular decoys to inhibit bacterial adherence (Boehm et al., 2005; Newburg et
al., 2005; Quintero et al., 2011; Quintero-Villegas et al., 2013; Shoaf et al., 2006).
Many pathogens utilize monosaccharides or short oligosaccharides as
receptors to bind to the surface of intestinal cells (Sharon, 2006) (Table 1).

!
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Pathogen
Campylobacter jejuni
Pseudomonas
aeruginosa
Escherichia coli (Type 1fimbriated)
Salmonella spp. (Type
1-fimbriated)

Carbohydrates Specificity
FucαGalβGlcNAc

Target Tissue
Intestinal

L-Fuc

Intestinal

Manα3Manα6Man

Urinary

Man

Intestinal

Klebsiella pneumoniae

Man

Respiratory and
Intestinal
Genital
Stomach

Neisseria gonorrhoeae
Helicobacter pylori
Streptococcus
pneumoniae

Man
NeuAc(α2-3)Galβ4GlcNAc
[NeuAc(β2-3)]0,1
Respiratory
Galβ4GlcNAcβ3Galβ4GlcNAc
[NeuAc(α2-3)0,1
Neisseria meningitidis
Respiratory
Galβ4GlcNAcβ3Galβ4GlcNAc
[NeuAc(α2-3)0,1
Haemophilus influenza
Respiratory
Galβ4GlcNAcβ3Galβ4GlcNAc
Table 1. Carbohydrates attachment sites for bacterial pathogens on animal
tissues. Adapted from (Ofek et al., 2003; Sharon, 2006)

Bacteria!

Receptors!
decoys!

Adhesins!
Receptors!
Cells!

!
Adherence!Model!

!An,-adherence!Model!

!
Figure 1. Anti-adherence model involving receptor analogs molecules for

reducing adherence of pathogens. Adapted from Ofek et al, 2003.
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Hence, future anti-adherence strategies to prevent pathogen infection

should first focus on identification and characterization of the molecular
interactions between bacterial adhesins and their receptors.

It may then be

possible to identify the specific targets and ultimately synthesize or produce new
molecular decoys that might lead to adherence inhibition.

NDO
β-Glucan

Structure
β-(1!3 and 1!4) D-Glcp
(Backbone); β-(1!36) DGlcp (branches; only on
some types)

Classification
Soluble, viscous,
highly
fermentable.
Insoluble, poorly
fermentable
Soluble and
viscous/gelforming in acid
solutions

Sources
Oat bran, barley
four

Chitin

β-(1!4)-D-GlcNAc

Chitosan

β-(1!4)-D-GlcNAc and
GlcN

Pectins

α-(1!4)-DGalA with
varying degrees of methyl
esterification (backbone)
and side groups
containing Rha, Gal.

Soluble, viscous,
highly
fermenatable

Fruits and
vegetables

Polydextrose

Random polymer of Glc,
sorbitol, and citric acid

Soluble, low
viscosity, partially
fermentable

Chemically
synthesized

Inulin/Fructo Fructose oligo- or polymer
oligosacchari linked β-(2!1) with Glc at
des
the non-reducing end

Inulin insoluble,
FOS soluble and
low viscosity;
highly fermentable

Galactooligo
saccharides

Soluble, low
viscosity, highly
fermentable

Oliginers of galactose

Shellfish
Alkali-treated
chitin

Onions,
Jerusalem
artichokes,
Enzymatically
synthesized
Βgalactosidase
treatment of
lactose

!
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Lactulose

D-Galp-β-(1!4)-D-Fru

Soluble, low
viscosity, highly
fermentable

Arabinoxylan

Heteropolymer with a
backborne of β-(1!3 or
1!4) –D-Xly complex
branches of Ara, Xyl, GlcA
and Gal.

Insoluble or
soluble and poorly
to highly
fermentable.

Glucose
isomerase
treatment of
lactose
Grain-based
materials, most
often wheat or
corn

Glc, glucose; Gal, galactose; Xyl, xylose; Ara, arabinose; Rha, Rhamnose; GlcA, Dglucuronic acid; GalA, galacruronic acid; GlcN, D-glucosamine; GlcNAc, N-acetyl-Dglucosamine.

Table 2. Main Non-digestible Oligosaccharides structure, classification and
sources. (Paeschke & Aimutis, 2011)

Human milk oligosaccharides (HMO)
Oligosaccharides are the major component in human milk, with a
concentration range of 8-12 g/L (Boehm et al., 2005). They represent the third
largest compound in milk. HMO are formed from 5 monosaccharides: D-glucose
(Glc), D-galactose (Gal), N-acetylglucosamine (GlcNAc), L-Fucose (Fuc), and
sialic acid (N-acetyl neuraminic acid (Neu5Ac) (Bode, 2006; Engfer et al., 2000).
HMO have a variety of biological activities beyond providing nutrition to the infant
(Barile & Rastall, 2013). There is abundant evidence that HMO can act as a
prebiotic, having a bifidogenic effect in breast-fed infants (Coppa et al., 2006).
Recent studies revealed that the catabolism and fermentation of HMO by
bifodobacteria have unique preferences on these glycans (Barile & Rastall, 2013;
Sela & Mills, 2010; Sela et al., 2011). Moreover, there are several reports
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showing that HMO can also serve as anti-adherence agents against pathogens
by acting as decoys to prevent binding of pathogens to epithelial cells (Barile &
Rastall, 2013; Bode, 2006; Newburg et al., 2004). (Manthey, Autran, Eckmann, &
Bode, 2014) HMOs isolated from pooled human milk was effective to inhibit the
adherence of EPEC (Enteropatogenic Escherichia coli) to cultural epithelial cells
in mice. Interestedly, C. jejuni binds to intestinal epithelial cells using 2’fucosyllactosamine receptor (Bode, 2006; Ruiz-Palacios et al., 2003), which is
the most prevalent OS in HMO.
Due to the complexity of the HMO, there has been growing scientific and
industrial

interest

in

natural

derived

NDO

as

galactooligosaccharides,

fructooligosaccharides and inulin in the supplementation of infant formulas
(Coppa et al., 2006).

Galactooligosaccharides (GOS):
GOS have attracted considerable commercial interest, since the presence
of galactose-containing oligosaccharides in human milk has been shown to
enhance the establishment of Bifidobacterium spp in breast-fed infants (Gibson
et al., 2010). Actually, there are several industries that produce GOS from
lactose (purified from cow’s milk whey) using the galactosyltransferase activity of
β-galactosidese to produce several oligomers of different chain lengths
(Macfarlane et al., 2008; Prenosil et al., 1987). The galactosylation activity of this
enzyme dominates lactose hydrolysis at high lactose concentration (Crittenden &
Playner, 1996; Sako et al., 1999; Smart, 1993).
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The anti-adherence properties of GOS are now well established. Under in

vitro conditions, GOS inhibited adherence of EPEC (enteropahogenic E. coli) to
HEp-2 and Caco-2 cells by 65% and 70% (Shoaf et al., 2006). More recently,
Quintero et al., 2011 reported that 16 mg/mL of GOS was also effective against
Cronobacter sakazakii, inhibiting adherence to HEp-2 cells by 56%. Other
studies have shown that adherence of Salmonella enterica serovar typhimurium
to HT-29 cells is inhibited by 5 mg/mL of commercial GOS (Bimuo®) (Searle et
al., 2010).

Pectic oligosaccharides (POS)
Pectins are commonly found in cell walls and seed mucilage of plants
(Paeschke & Aimutis, 2011). They are commercialized for different industrial
applications due to their potential functional properties. Oligosaccharides derived
from pectins (POS) have gained attention as a candidate prebiotics (Hothkiss et
al., 2003). POS are form by partially methyl esterified homogalacturonan
backbone with periodic interruptions by regions of alternating galacturonic acid
and rhamnose residues (Rastall, 2010).
POS have been assessed for their ability to stimulate growth of beneficial
bacteria, including Lactobacillus (Mandalari et al., 2006) and Bifidobacterium
(Manderson et al., 2005; Olano-Martin et al., 2002). In addition to their putative
prebiotic activity, POS have also been recognized for their ability to inhibit the
adherence of pathogens (Hotchkiss et al., 2003; Holck et al., 2014), as well as for
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their immunomodulatory and anti-carcinogensis properties. (Holck et al., 2014;
Morris et al., 2013).

Fructooligosaccharides (FOS):
FOS are a mixture of oligosaccharides composed of glucose and
repetitive fructosyl residues in β- (2!1) linkage or β- (2!6) linkage (Boehm et
al., 2005). FOS is naturally present in a variety of food products, including onion,
garlic, salsify, leek, asparagus root, and Jerusalem artichoke tubers (Molis et al.,
1996). There are two main industrial processes to obtain FOS. The first one is
produced from sucrose via transfructosylating enzymes and the second one via
partial hydrolysis of inulin by endoglycosidases (Coussement, 1999; Hirayama et
al., 1989; Molis et al., 1996). FOS is one of the best studies NDO in both in vitro
and in vivo models. Like other NDOs, FOS resists hydrolysis, and is able to
reach the colon intact. In the colon, inulin is fermented by resident symbiotic
anaerobic bacteria, especially bifidobacteria (Walker & Duffy, 1998) (Roberfroid,
1996)

Chitooligosaccharides (CHOS)
CHOS are produced enzymatically or chemically from chitosan.
Structurally, CHOS consist of a linear heteropolymer of β (1!4) linked N-acetylD-glucosamine (GLcNAc) and its deacylated counterpart D-glucosamine (GlcN)
(Quintero-Villegas et al., 2013). Chitosan is generally produced commercially
from crab and shrimp wastes with different degrees of acetylation and molecular
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masses, thus presenting a variety of properties (Ganan et al., 2009) . Chitosan
has received increased attention for its natural source and bioactivity, and it is
now used in different applications for foods and pharmaceuticals (Devlieghere et
al., 2004; Ganan et al., 2009). The mechanism behind the bioactivity of CHOS is
poorly understood. However, the sequences of GlcNAc and GLcN units in CHOS
has been reported to be important for binding affinity, and for ensuring selectivity
for pathogens (Aam et al., 2010)
There are several reported studies that have assessed the antimicrobial
properties of CHOS against Campylobacter spp. One study showed that C. jejuni
and C. coli were highly sensitive to chitosan. The minimal inhibitory concentration
(MIC) of chitosan ranged from 0.05% to 0.5% and the most effective
antimicrobial fractions were chitosan with a MM of 120 KDa (Ganan et al., 2009).
Another study reported that the biological properties of CHOS on Campylobacter
depended on the composition of the fraction analyzed (Liu et al., 2008). They
suggested that the high and medium molecular weight of chitosan obtained from
chitosan with a fraction of acetylation (FA) of 0.09 have stronger inhibition effect
compared with the chitosan (FA 0.25) (Mengíbar et al., 2011).

Mannan oligosaccharides (MOS)
MOS are derived via partial hydrolysis of the polysaccharide, mannan,
which consists of α-1,4 linked mannose monomers (Tester & Al-Ghazzewi,
2013). They are obtained commercially either from plant material or from yeast
cell walls. Mannose-based carbohydrates could be a promising natural agent for
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reducing adherence of enteropathogenic bacteria, since these pathogens rely on
adhesins that bind to mannose receptors (Santin et al., 2001). Yeast
mannanproteins have also been shown to enhance the growth and persistence
of some lactic acid bacteria reach and colonize the gut (Ganan et al., 2012).
Extracts rich in mannanproteins also have shown to inhibit the adherence of
some foodborne pathogens, such as of Campylobacter jejuni (Ganan et al.,
2009); E. coli (Baurhoo et al., 2007); and Salmonella (Fernandez et al., 2002;
Posadas et al., 2010).
Arabinoxylan oligosaccharides (AXOS)
Arabinoxylan (AX) are the second most abundant oligosaccharides in
hemicellulose fraction of softwoods (Faber, 2012). Arabinoxylan oligosaccharides
(AXOS) are derived from wheat bran by extensive hydrolysis of the AX present,
but are not commercially available (Van Craeyveld, 2009). AXOS consists of β1,4 linked backbone of xylose with arabinose side chains.
AXOS are similar to other well know inulin and other prebiotic in that they
have shown to have a bifidogenic effect (Grootaert et al., 2007; Paeschke &
Aimutis, 2011; Pastell, et al., 2009; Vardakou et al., 2008). Wheat-derived AX
polysaccharides fractions have been shown to be fermented in vitro by human
fecal microbial communities (Hughes et al., 2008). However, more information
about the structure-activity of both AX and AXOS, and the development of
economically viable process to manufacture these novel oligosaccharides are
required (Paeschke & Aimutis, 2011).
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Cranberry Extract
Cranberry (Vaccinium macrocarpon Ait., family Eri- caceae) fruit juice is
traditionally used to treat and prevent urinary tract infections (Burger et al., 2000;
Howell et al., 2005). Most of the studies have been performed in vitro with
cranberry juice cocktail and concentrated cranberry extract. These studies have
shown these cranberry products have bactericidal, bacteriostatic and antiadhesion properties against different pathogens that colonize the stomach, the
mouth and the urinary tract (Sobota, 1984; Steinberg et al., 2005; Watson &
Preedy, 2010; Zafriri et al., 1989). A-type proanthocyanidins of cranberry juice
cocktail has been shown to inhibit the adherence of P-fimbriated uropathogenic
E. coli to uroepithelial cells. Therefore, these compounds may be responsible for
the beneficial effect on UTI prevention (Howell et al., 2005; Zafriri, et al., 1989).
The high molecular mass constituents of cranberry juice has been shown
to inhibit adherence of H. pylori BZMC-25 to human erythrocytes by inhibiting the
sialic acid-specific adhesion (Burger et al., 2000). The non-dialyzable material
(NDM) of cranberry extract had been reported as an anti-adhesion and antibiofilm agent against S. sorbinus (Steinberg et al., 2005). However, an in-vivo
study showed that dietary supplementation with low (1%) and high (30%) content
of proanthocyanidins from cranberry extract had no significant effect in the
colonization of C. jejuni in young chicks (Woo-Ming, 2012).
Conclusion
The ability of some non-digestible oligosaccharides to prevent bacterial
adhesion is a promising strategy to interfere with the initial step of bacterial
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pathogenesis. Many well studied NDOs, such as GOS and FOS have been used
as food ingredients for their prebiotic effect, especially to stimulate the growth of
Bifidobacterium spp and to modulate gut microbiota. In addition, other NDOs
have been proposed for their prebiotic properties and also to prevent pathogens
attachment to epithelial host cells. Other oligosaccharides, including natural plant
derived molecules like cranberry extract, have been investigated for their ability
to interfere with the adherence of some pathogens.
Antibiotic growth promoters are used in animal production to enhance
animal performance and reduce pathogens colonization. However, bans and
restrictions on the use of AGPs have led researchers and manufacturers to
identify alternative compounds that have similar function to antibiotics. The antiadherence approach has gained considerable interest for agricultural purposes.
Thus, the development of novel natural derived components to prevent
pathogens colonization in animals and human is worthy of exploration. However,
further investigations are required to understand the structure and functional
properties of anti-adherent agents and the interaction of bacterial adhesins with
the host cell receptors.
Campylobacter spp. are recognized as one of the leading human
foodborne pathogens. Moreover, it is known that this bacterium is well
established in the gastrointestinal tract of poultry, and the consumption of
contaminated meat is the main significant risk factor for human infection.
Therefore, reducing the prevalence of Campylobacter spp. in poultry could
decrease the incidence of campylobacteriosis in humans. NDOs are promising
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agents to be included in poultry diets as a supplement to enhance performance
and reduce adherence of pathogenic bacteria.
The objectives of the research described in this thesis were to:
1. Assess the ability of mannan oligosaccharides (MOS) and cranberry high
molecular weight component (HMW) to inhibit the adherence and invasion of
three strains of C. jejuni and two strains of C. coli to HEp-2 cells.
2. Determine which component (mannan oligosaccharides or β-glucan fraction) is
responsible for the anti-adherence effect.
3. Test the additive effect of a combination of MOS and HMW.
4. Determine the ability of pectic oligosaccharides to inhibit the adherence and
invasion of three strains of C. jejuni and two strains of C. coli to HEp-2 cells.
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Chapter 2
Mannan oligosaccharides as animal feed supplement
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Introduction
Naturally derived non-digestible oligosaccharides (NDO) have attracted
considerable interest among industrial scientists, due to their functional and
biological properties in human food and animal feed.

In particular, these

oligosaccharides have shown to have beneficial effects on animal health by
modulating

gut

microbiota,

suppressing

pathogenic

bacteria,

enhancing

immunity, and facilitating mineral absorption (Paeschke & Aimutis, 2011; Patel &
Goyal, 2011; Van Loo et al., 1999).
In the past decades, sub-therapeutic levels of antibiotics have been widely
used in livestock animals as growth promoters (Dibner & Richards, 2005; Gaggìa
et al., 2010). However, the World Health Organization, the American Medical
Association, and the American Public Health Association have approved these
substances be banned or restricted for animal production applications (Graham &
Boland, 2007). The main motivation for restricting GPAs is due to the
transmission of antibiotic resistant genes among microorganisms that colonize or
infect animals. Ultimately, the spread of pathogenic bacteria that are resistant to
antibiotics would pose significant risks to human health.
Recently, NDOs, and mannan oligosaccharides (MOS), in particular, have
been reported to serve as alternative agents to replace growth promoting
antibiotics in animal production (Patel & Goyal, 2011; Yang et al., 2009, Baurhoo
et al., 2007; Ferket et al., 2002; Kim et al., 2011; Miguel et al., 2004; Soren et al.,
2013). MOS are derived from the yeast cell walls (Feuillat, 2003), and are
inexpensive by-products from industrial processes (i.e. brewers, bakeries).
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Several studies have shown beneficial effects of MOS supplementation in animal
feed, such as reduce the colonization of some pathogens like E. coli and
Salmonella spp. (Fernandez et al., 2002; Line et al., 1998; Santin et al., 2001),
immune modulation (Sang et al., 2009; Staykov et al., 2007), and improve growth
performance and welfare in livestock (Sang & Fotedar, 2010; Torrecillas et al.,
2011; Zhao et al., 2012).
The present review paper describes the main applications of mannan
oligosaccharides in animal feed and their role as alternative components to
replace growth-promoting antibiotics.

Mannan oligosaccharides
Mannan oligosaccharides (MOS) are non-digestible oligosaccharides
derived via partial hydrolysis of the polysaccharide, mannan (Tester & AlGhazzewi, 2013a).

The latter consists of α-1,4 linked mannose monomers.

Partial hydrolysis yields MOS with degree of polymerization (DP) ranging from 6
to 8 (Bland et al., 2004).

Currently, most commercial sources of MOS are

derived from the cell walls of bakers’ or brewers’ yeast strains of Saccharomyces
cerevisiae. They are used primarily as supplements for animal feed (Halas &
Nochta, 2012). The actual composition of yeast-derived MOS depends on
several factors, including species, growth phase at harvest, and growth or
fermentation conditions.
Other sources of MOS have also been considered. Plant-derived MOS
have been studied from hemicellulose plant cell walls, such as konjac (Holck et
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al., 2014). Spent coffee grounds, coffee beans and waste coffee mannans have
also been studied (Moreno & Sanz, 2014), but no commercial sources for these
products currently exist.

MOS from yeast cell wall
The yeast cell wall is a major constituent of the total yeast biomass,
accounting for 25 - 30% of dry weight of the cell (Klis et al., 2010; Latgé, 2007) .
Yeast cell walls of S. cerevisiae are composed of mannoprotein (35%), β-1,3
glucan (25%), β-1,3 glucan bound to chitin (35%), β-1,6 glucan (5%) and small
amount of chitin (1-2%) (Feuillat, 2003; Orlean, 2012).
The cell wall proteins exist as glycoproteins that are highly modified with
O-and N-linked oligosaccharides. These oligosaccharides are comprised mainly
of mannose residues, collectively known as mannan (Gupta et al., 2012). The
mannan backbone is homopolymeric, containing mannose residues only or
heteropolymeric, with side chains containing other sugars. The latter include
mannose, glucose, rhamnose, and galactose, forming glucogalactomannan,
rhamnogalactomannan, and galactomanan oligosaccharides (Bowman & Free,
2006; Gupta et al., 2012; Leal et al., 2010).
Many of the proteins found in yeast cell walls are water-or detergent-soluble,
and only a few are covalently linked to the polysaccharides. These glycoproteins
are classified in two groups: proteins covalently linked to β-1,3 glucan through
glutamine reside; and proteins covalently linked by a glycosylphophatidyl inositol
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anchor to the β-1,6 glucan of a β-1,3/ β-1,6 glucan core (Gupta et al., 2012; Klis
et al., 2006; Latgé, 2007).

Biological properties of MOS
Although non-digestible oligosaccharides, MOS have no known direct
nutritive value in animal feed, however, they have been suggested to enhance
gut health (Halas & Nochta, 2012). Several properties of MOS that make them
useful as nutritional supplements for animal feed products have been described
(Table 1) (Ferket et al. 2002 and Soren et al. 2013). In general, MOS should be
non-digestible, not absorbed in the stomach and small intestine, and they should
reach the colon intact. In the colon, MOS and mannose-based glycans could
have prebiotic activity and be fermented by desirable members of the gut
microbiota.
The yeast-derived MOS and β-glucan components share similar
properties, but are different in several important respects.

MOS are

polysaccharides-protein complexes, and β-glucans are polymers of glucose. βglucans have been considered as immunoestimulators of macrophages and
other immune effector cells (Chong, 2009). Szymanska-Czerwinska et al., 2009
have reported that the combination of MOS and β- glucans increase cytokine
levels and the percentage of lymphocyte subpopulation in calves. More recent
study made by Zhang et al., 2012 shown that broiler chickens fed with β-glucans
from yeast cell wall enhance cell mediated immune response by modulating the
production of cytokines.
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Several studies have suggested another important property of MOS.

Specifically, mannan oligosaccharides can inhibit the binding of pathogenic
bacteria to the mucosa of the gut and therefore reduce colonization and the
onset of infections (Klemm & Schembri, 2000; Tester & Al-Ghazzewi, 2013b). In
the GIT, MOS act as high affinity ligands, providing competitive binding sites for
specific enteric bacteria (Ofek & Beachey, 1978). This binding is usually
mediated by bacterial fimbriae that contain terminal adhesin residues. Fimbriae
thus serve as adhesive organelles that enable bacteria to target specific host
tissues, to which they bind to and colonize (Corrigan et al., 2012). Mannose
residues are bound preferentially by type I fimbria, present in several enteric
pathogens.
Extracts rich in mannoproteins have been shown to be effective, in vivo,
against Campylobacter jejuni (Ganan et al., 2009; McSweegan & Walker, 1986) ,
Escherichia coli (Baurhoo et al., 2007) and Salmonella (Fernandez et al., 2002;
Oyofo et al., 1989). Most of these in vivo studies have been conducted with
broiler

chicks,

pigs,

fish,

cattle,

and

companion

animals.

Dietary

supplementations with MOS from yeast extracts have been used in livestock
animals at relatively low concentrations (between 0.5 - 5.0 kg/ton), resulting in
enhanced overall performance and reduced inhibition and colonization of enteric
pathogens (Baurhoo et al., 2007; Castillo et al., 2008; Torrecillas et al., 2011;
Waldroup et al., 2003; Zhao et al., 2012).
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MOS production
As noted above, most of the commercial MOS products are derived from

various strains of yeast. The most common yeasts used for MOS product are
from the genus of Saccharomyces and Candida. In general, yeast cells are
grown using common techniques used in the bakers yeast and brewers yeast
industries (Halas & Nochta, 2012). Nutrient-rich media are used to achieve high
cell densities, and often include diluted molasses and sulfite waste liquor. Once
cell growth has reached a sufficiently high cell density, the yeast cell wall fraction
(containing MOS) is extracted. This is usually done by mechanical or enzymatic
methods and rely on autolysis, hydrolysis (i.e., via β–mannanases, pectinases, αgalactosidases and cellulases) or physical means (Katz & Brown, 2007)
Autolysis of yeast cell wall is one of the most common methods to extract
the MOS fraction. For example, Agrimos®, manufactured by Lallemand Animal
Nutrition, is produced by autolysis of yeast cells at high temperatures and at
controlled pH. The yeast extract and cell wall is separated by centrifugation, and
the cell wall fraction is spray dried and packaged.

Antibiotics in animal production
Antibiotics have been used to promote growth in livestock animals for
many decades (Ferket et al., 2002). In vivo studies have reported that inclusion
of regular low doses of antibiotics in animal diets provides several beneficial
performance effects in animals, including increases in weight gain, improved feed
efficiencies, reduced mortality, and inhibition of pathogen colonization in

!

!

42!

intensive production systems (Gaskins el al., 2002; Phillips et al., 2004).
Ultimately, these benefits are suggested to reduce overall animal production
costs and to provide economic benefits that are distributed along the food chain
(Ferket, 2003). However, the widespread use of antibiotics in animal production
has also been suggested to contribute to the emergence and spread of antibiotic
resistance bacteria (Phillips et al., 2004).
Controlling the transmission of pathogenic bacteria at the farm level is now
a major of concern in animal production. In particular, the poultry industry has
identified contamination of raw poultry products to be a consequence of high
populations of pathogenic bacteria in the gastrointestinal tract of poultry animals
(Ferket et al., 2005).

Mode of action of growth promoters
Although widely used in animal agriculture (Looft et al., 2012), the
mechanisms by which antibiotics promote growth are not fully understood
(Dibner & Richards, 2005; Graham & Boland, 2007). Many hypothesis have
been suggested to explain the mechanisms of action for the growth-promoting
effect of antibiotics in production animals (Giguère et al., 2013)
Gaskins et al, 2002 proposed four mechanisms of action of GPAs: (1)
inhibition of sub-clinical infections; (2) reduction of growth-depressing microbial
metabolites; (3) reduction of microbial use of nutrients; and (4) enhanced uptake
and use of nutrients. More recently, Giguère et al., (2013) suggested additional
hypotheses to account for the growth-promoting effect of antibiotics in livestock
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animals (Table 1), such as: stimulation of intestinal synthesis of vitamins by
bacteria; reduction in total number of bacterial in the GIT by reducing competition
between microorganism and host animals for nutrients; reducing pathogenic
bacterial; inhibition of bacterial urease; improve energy efficiency of the gut;
reduced immune stimulation; modification of intestinal enzyme activity; inhibition
of bacterial cholytaurin hydrolases activity; improve nutrient absorption from
morphological changes to small intestinal epithelium. In contrast, Bedford, 2000
reported that GPAs have no beneficial effect in germ-free chicks, indicating that
the direct effect is due to alteration in the gut microbiota composition rather than
interact with the physiology of the animal (Conejos et al., 2012).

Effects of antibiotics in animals
After antibiotic administration, animals are more susceptible to pathogens
colonization because of the loss of the resident microbiota (Ferket, 2004). The
stability of the gut microbiota is important for maintenance of a healthy barrier
against pathogen infection in animals (Gaggìa et al., 2010). Administration of
competitive exclusion cultures as probiotics (Fedorka-Cray et al., 1999; Sohail et
al., 2010) or feeding prebiotic oligosaccharides have been used in livestock to
enhance the stability of microbiota (Ferket, 2004; Fernandez et al., 2002).
Accordingly, older animals are, in general, more resistant to colonization by
enteric pathogens than young animals because they have more stable diverse
gut microbiota that compete excluding pathogen colonization (Ferket, 2004).
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MOS as new growth promoter agent
Since the use of antibiotics has been banned in Europe and some have
been restricted in United States, there are serious concerns about the possibility
that antibiotic-resistant genes can be transferred to human pathogens
(Chowdhury el al., 2009). Hence, the animal production industry has been
seeking to identify or develop alternative products to reduce reliance on
antibiotics while maintaining production efficiency (Ferket et al., 2005).
MOS may be an effective alternative to replace antibiotic growth
promoters (AGPs), because they have been shown to have similar effect on
animal performance (Baurhoo et al., 2007; Castillo et al., 2008; Fritts &
Waldroup, 2003). MOS were first introduced as a feed additive for poultry in 1993
(Bio-MOS®, Alttech Inc.). This carbohydrate has been recognized to have
potential properties to inhibit the adherence pathogen to the surface of epithelial
cells.

Alternatives to antibiotics in poultry production
Although the use of antibiotics as growth promoters in the poultry industry
has been widely accepted for many years, there is now considerable concern
about their possible effects on public health (Dibner & Richards, 2005).
Proponents of this practice have suggested that GPAs are an essential tool to
maintain animal productivity by increasing average weight of broilers, reducing
the amount of feed required to reach market weight, and ultimately decreasing
the cost of chicken products for consumers (Graham & Boland, 2007; Smith,
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2002). However, alternative inexpensive and natural agents are now being used
for pathogen control and to enhance the overall performance of the animal and
replace the use of GPAs. These include probiotics and prebiotics, herbal
products, vaccines, and sanitation practices to prevent vertical transmission of
pathogens and promote gut health (Stanley & Jones, 2003; Yano et al., 2013).

MOS in poultry production
Mannan oligosaccharides products, especially those derived from the cell
wall of S. cerevisiae, are extensively used as natural feed additives in poultry due
to the beneficial effect in the performance and gastrointestinal health (Xiao et al.,
2012). However, studies have shown contradictory results in chickens and
turkeys. In some studies, supplementation of MOS in the diets had significant
effects on the performance (i.e., increase in body weight, feed conversion, feed
intake) of the animal (Baurhoo, et al., 2007; Fernandez et al., 2002; Waldroup et
al., 2003). Similarly, decreases in pathogenic bacteria in the gut, stimulation of
the immune response, and elevating the strength of the intestinal mucosa have
also been reported (Corrigan et al., 2012; Fernandez et al., 2002; Fritts &
Waldroup, 2003). In contrast, other studies that reported that there was no
significant effect when MOS was included in the diets of poultry compared with a
normal diet or with diet with antibiotic supplementation (Table 1).
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MOS in swine production
In swine nutrition, supplementation of feed with prebiotics and probiotics

have been reported to have beneficial effects on growth performance,
gastrointestinal functional, and health of pigs (Zhao et al., 2012). Previous
studies have demonstrated that mannan oligosaccharides improved the daily rate
of weight gain and/or feed efficiency during early stages of nursery pigs (Davis et
al., 2002; Miguel, Rodriguez et al., 2004; Zhao et al., 2012) and in sow diets
during late gestation and lactation (Halas & Nochta, 2012). However, there are
other studies that reported less consistent results, specifically, that MOS had no
effect in the performance of young pigs (Castillo et al., 2008; Wenner et al.,
2013). Although, there are some conflicting results with the effect of MOS as a
growth promoter in pigs, other studies have shown that the supplementation with
MOS in the diet reduce the total coliforms counts in the gut and appears to have
immune modulation effect in the post weaning-period in pigs (Davis et al., 2004;
Kim et al., 2011) (Table 2).
Weaning is a critical period in piglets that is associated with stress,
diarrhea, and depressed growth rates (Liu et al., 2008). Antibiotics have long
been used to control and prevent these post weaning symptoms. MOS as a feed
additive are suggested to be an alternative of the GPAs in swine, based on the
relevant literature that have shown these products maintain gut health, interfering
with pathogen colonization and enhancing the defense mechanisms in post
weaning pigs and in other livestock animals.
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MOS in fish production
Aquaculture production have been recognize as a growing industrial

sector that have a huge socio-economic impact in developing and emerging
countries (Yousefian & Amiri, 2009). Indeed, one of the most important priorities
in the aquaculture industry is to produce fish and seafood under sustainable and
safe conditions. As for poultry and swine, feed supplements are needed to
improve animal health, reduce mortality, improve growth performance, and
reduce or eliminate antibiotics in the diets (Torrecillas et al., 2007). The use of
non-digestible oligosaccharides have shown promise as preventive and
environmentally friendly alternatives to antibiotics in aquaculture, and to improve
overall health especially for fishes and crustacean (Bachere, 2003; Soltanian et
al., 2007) that may lead to expand and maintain this industry.
The mechanism of action of MOS in fish production appears to be similar
to other animal applications. These products may prevent pathogen colonization,
enhance overall health and welfare, and promote gut maturation and growth
(Genc et al., 2007; Sado et al., 2008; Torrecillas et al., 2011). Incorporation of
MOS in the diet has been reported to promoted resistance to bacterial infection in
Cobia (Rachycentron canadum)(Salze et al., 2008), rainbow trout (Salmo
gairdneri irideus) (Staykov et al., 2007), sea bass (Dicentrarchus labrax)
(Torrecillas et al., 2011), channel catfish (Ictalurus punctatus) (Peterson et al.,
2010), marron (Cherax tenuimanus) (Sang et al., 2009). However, other studies
showed no effect of MOS on growth performance of aquatic species ( a
Dimitroglou et al., 2009; Pryor, 2003). For example, investigations with Gilthead
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sea bream (Sparus aurata) (A. Dimitroglou et al., 2010), Atlantic salmon
(Grisdale-Helland,

et

al.,

2008)

revealed

no

significant

effect

when

supplementing diets with MOS.

Conclusion
The worldwide trend toward eliminating the uses of antibiotic growth
promoters for animal production has led researchers to seek new strategies to
enhance growth, increase feed efficiency, reduce pathogen colonization, and
improve overall performance in livestock animals. Mannan oligosaccharides are
naturally derived molecules that may have the properties necessary to provide
benefits similar to antibiotics. However, further research must be conducted to
identify the function and mechanism of action of these substances. Ultimately,
the use of MOS and other similar material to inhibit specific pathogens in
livestock animals may have important implications for improving food safety.
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Table 1. In vivo uses of mannan oligosaccharides in poultry
Diet

0.2% MOS
BioMOS

0.1% MOS
BioMOS

0.2% MOS

2.5 % MOS

0.15% MOS

0.10 % BioMOS

0.22% MOS
BioMOS

Performance
Significant
improvement on feed
conversion. No effect
on
body
weight,
mortality and breast
meat yield.
Higher body weight
gain,
better
feed
conversion in broiler
chickens and higher
villus height at 7 days
of age.

No reported
Body weight gain, feed
intake
and
feed
conversion ratio of
broilers by adding
MOS
are
not
significant different (6
weeks)

Gut Health
References
Increased
the
population
of
bifidobacteria and (Baurhoo et
lactobacilli in the al., 2007)
ceca, after 42 days
of treatment

No reported

S.
enteritidis
colonization
decreased
over
time in chick fed
with MOS diet.
Increased
Bifidobacterium
spp.,
while
decreasing member
of
Enterobacteriaceae
and Enterococcus
spp.,

Body weight and feed
conversion ratio are
no
significantly No reported
affected by the MOS
diet.
Significant
improvement in feed
conversion after the
20 week of inclusion of
MOS. Body weight No reported
gain and mortality are
no
significantly
affected
by
the
treatment.
Identified
672
No reported
genes expressed in
the
jejunum
by

(Waldroup et
al., 2003)

(Santin et al.,
2002)

(Fernandez et
al., 2002)

(Yalcinkaya
et al., 2008)

(Fritts and
Waldroup,
2003)

(Xiao et al.,
2012)
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MOS
supplementation
that are involved in
the
diverse
biological functions
including
energy
production,
cell
death, and protein
translation.
Significant
reduction in the
colonization
of
challenged
Salmonella
typhimurium
in
chickens fed with
MOS
diet.
Campylobacter
jejuni colonization
was not significantly
affected with the
diet.
MOS
supplementation
displayed
significantly altered
bacterial community
structure in young
turkeys.

0.1% Yeast S.
boulardii

No significant
differences in body
weight, and feed
conversion ratios.

0.1% MOS
(BioMOS)

No reported

0.3 and 0.5%
MOS (BioMOS)

The MOS supplement
let
to
minor
improvement in body
No reported
weight
but
no
improvement in feed
conversion ratio.

(Line et al.,
1998)

(Corrigan et
al., 2012)

(lji et al.,
2001)
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Table 2. In vivo uses of mannan oligosaccharides in pigs
Diet
0.2 % MOS
BioMOS

0.1% MOS

0.2% MOS
BioMOs

0.2% MOS

0.2% MOS

3 % brewers
dried yeast

Performance
Gut Health
Improve efficiency of Decreased
weight gain during enterobacteria
starter
period
of counts in jejunum.
piglets.
Significant
improvement
in
average daily gain
and average daily
gain intake in pigs fed
with MOS during 28
days.
No
statistical
difference in growth
rate, average daily
feed intake and feed
conversion in weaning
pigs fed with MOS
diet.
Improve in daily feed
intake
during
the
starter
period
(2
weeks).
Feed conversion was
improved.
Increased
average
daily
gain
and
average daily feed
intake of nursery pigs
between 12 to 14
days of MOS diet.

None effect in the
growth performance
of nursery pigs.

References
(Castillo et al,
2007)

No reported

(Zhao et al,
2013)

No reported

(Wenner et
al, 2013)

Pigs fed with MOS
diet
decreased
enterobacteria
(Castillo et
counts
in
the al., 2007)
jejunum.

No reported

(Lemieux et
al., 2003)

Total
coliforms,
Escherichia coli, and
Clostridium
perfringens in feces
were not affected by
diet. Bifidobacteria (White et al.,
spp. counts were 2002)
lower in pigs fed the
yeast
diet
and
lactobacilli
counts
were higher in pigs
fed yeast.
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0.2% MOS

0.3 % MOS

0.3% MOS

Average daily gain,
average daily feed
intake and gain: feed No reported
ratio increased with
MOS diet from day 0
to 10 in weanling pigs.
Increased the average
daily
gain
and
average daily feed No reported
intake in the pigs fed
with MOS diet
Increases
of
apparent coefficient
of digestibility, and
No reported
in villi height of the
animals fed with
MOS.

(Davis et al.,
2002)

(Rozeboom
et al, 2005)

(Conejos et
al, 2012)
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Table 3. In vivo uses of mannan oligosaccharides in fish and crustacean.
Diet

Performance

0.2% MOS

No reported

0.2% and 0.4%
MOS BioMOS

Fish fed with 0.2%
and 0.4% MOS
shown significant
increase body weight
and growth rate.

0.2% and 0.4%
MOS

No significant effect
in the body weight,
feed conversion, and
specific growth rate
and protein
efficiency ratio in sea
bream fed with MOS
diet for 9 weeks.

Gut Health
References
Viable
intestinal
bacterial population
was
significant
reduced (approx. 2 (Staykov et
Logs)
like al., 2007)
Aeromonas/Vibrio
spp. in juvenile trout
fed with MOS.
European sea bass
intestinal villi length
was no affected by
MOS diet.
0.4%
MOS
significantly improved
head
kidney (Torrecillas et
al., 2007)
macrophages
phagocytic
activity.
Significant reduction
in the challenge of V.
alginolyticus
in
presence of 0.4%.
MOS diet increased
microvilli density in
both the anterior and
posterior.
intestinal
regions.
No
significant effect in
the gross of villi (Dimitroglou
et al., 2010)
structure.
MOS diet alters the
intestinal microbiota
and morphology of
gilthead sea bream.

Fish fed diets with
0.4% MOS had best
weight gain but it is No reported
no
significant
different from the

(Sado et al.,
2008)
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control.
Feed
conversion decrease
with the increase
levels of MOS.

0.3% MOS

0.4 % and 0.6 %
MOS

0.3% MOS

Enhanced
growth
performance
and
feed conversion ratio
was observed in
shrimp fed with MOS
for 48 days.
Feed
consumption
was improved in fish
feed
with
MOS.
Reduction in feed
intake was found in
fish with the inclusion
of MOS.
No significant effect
in the growth
performance in fish
fed with MOS.

0.4% MOS

No reported

0.4% MOS

Significant
higher
growth
rate
and
average weekly gain
in lobster fed with
MOS for 56 days

No reported

(Genc et al.,
2011)

Enhancement in the
number
of
cells
secreting acid mucins
(Torrecillas et
in posterior gut of fish
al., 2011)
fed MOS.
No significant effect
in the gastrointestinal
morphology or spiral
valve villi structure
was found in fish fed (Pryor, 2003)
with
MOS
supplementation.
Gut mucosal folds
height, width and
folds surface area
were increased in fish
fed with MOS diet
during 8 weeks
(Torrecillas et
al., 2011)
Enhancement in the
number
of
cells
secreting acid mucins
and in gut mucus
lysozyme activity.
Lower mortality of
lobster fed with MOS (Sang and
when Vibrio spp was Fotedar,
challenge for 7 days. 2010)
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Chapter 3
Adherence inhibition of Campylobacter jejuni and Campylobacter coli to HEp2 cells by mannan oligosaccharides and cranberry high molecular weight
component.
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Abstract
Campylobacter infections are a leading cause of human bacterial gastroenteritis
in the United States and a major cause of diarrheal disease throughout the world.
Poultry has been identified as a major reservoir for this pathogen, and
contaminated chicken meat is considered a significant risk for human infection.
Colonization and subsequent infection and invasion of Campylobacter require
that the organism adheres to the surface of host cells as the first and one of the
most important steps in bacterial pathogenesis. Agents that inhibit adherence
could therefore be used prophylactically to reduce Campylobacter carriage and
infection. Yeast mannan oligosaccharides (MOS) have been used as a feed
supplement in livestock animals to replace growth-promoting antibiotics.
However, some non-digestible oligosaccharides as MOS may also have the
ability to prevent gastrointestinal infections by inhibiting pathogen adherence.
Cranberry juice has been used to treat and prevent urinary tract infections, due in
part to a high molecular weight (HMW) fraction that has anti-adherence activity
against pathogens. The goal of this study was to assess the ability of MOS,
purified MOS, cranberry HMW and the combination of MOS and HMW to serve
as anti-adherence agents against C. jejuni ATCC 29428, C. jejuni ATCC 33291,
C. jejuni ATCC 700819, C. coli ATCC 43485 and C. coli ATCC BAA-1061.
Adherence experiments were performed using a human epithelial tissue cell line
(HEp-2) in the absence or presence of MOS, pMOS, HMW and MOS/HMW.
Significant reductions in adherence of C. jejuni ATCC 29438, C. jejuni ATCC
700819, C. jejuni ATCC 3329 and C. coli ATCC 43485 were observed in the
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presence of MOS/pMOS (up to 40 mg/mL) and with HMW (up to 3 mg/mL).
There was no significant effect in the adherence of C. coli ATCC BAA-1061.
There was no additive effect in adherence of all the strains with the blend of
MOS/HMW. The results obtained in this work suggest that MOS, pMOS and
HMW may have an anti-adhesive effect on specific strains of C. jejuni and C. coli
and directly inhibit the adherence to HEp-2 cells. These results suggest that both
components MOS and HMW could be used to reduce Campylobacter
colonization in livestock animals and prevent the onset of human infections.

Introduction
Mannan oligosaccharides (MOS) are non-digestible oligosaccharides
derived via partial hydrolysis of the polysaccharide, mannan (Tester & AlGhazzewi, 2013). The latter consist of α-1,4 linked mannose monomers and are
obtained commercially either from plant material or from yeast cell walls. In
particular, brewers’ and bakers’ yeast strains of Saccaromyces cerevisiae are
widely used to produce MOS products for animal nutrition applications (Halas &
Nochta, 2012). Yeast cell walls of S. cerevisiae are composed of mannoprotein
(35 %), β-1,3 glucan (25%), β-1,3 glucan bound to chitin (35%), β-1,6 glucan
(5%) and small amount of chitin (1-2%) (Feuillat, 2003; Orlean, 2012).
Mannose-based carbohydrates could be a promising natural agent for
reducing adherence of enteropathogenic bacteria, since because bacterial
adherence in the gut is often mediated by binding of bacterial lectins to receptors
containing D-mannose (Ganan et al., 2012; Shoaf et al., 2006). MOS as non-

!

!

66!

digestible oligosaccharide have no direct nutritive value in animal feed, however
they have been shown to maintain or promote gut health (Halas & Nochta, 2012).
Extracts rich in mannanproteins have been shown to have a bioprotective effect
against some pathogens such as Campylobacter jejuni (Ganan et al., 2009;
Mcsweegan, 1986; Russell & Blake, 1994), Escherichia coli (Baurhoo et al, 2007)
and Salmonella (Fernandez et al., 2002; Oyofo et al., 1989). Most studies have
been conducted in-vivo with broiler chicks and pigs, and to a less extend in cattle
and swine. Dietary supplementations with mannan oligosaccharides from crude
yeast extract have been used in livestock animals, resulting in enhance overall
performance and inhibiting colonization of enteric pathogens.
Another natural source of anti-adherence substances is derived from
cranberry juice. Cranberry fruit juice has traditionally been used to treat and
prevent urinary tract infections (UTI) (Vinson et al., 2008; Zafriri et al., 1989). In
particular, two main components in cranberry juice have been shown to reduce
adherence of E. coli to uroepithelial cells. Fructose inhibits adherence of E. coli
phenotypes possessing type 1 (mannose-sensitive) fimbriae (Foo et al., 2000;
Zafriri et al., 1989), and type-A proanthocyanidins (PACs) inhibits adherence of
P-fimbriated E. coli in vitro (Howell et al., 2005). Thus, these compounds may be
responsible for the beneficial effect of cranberry juice on UTI prevention.
Cranberry PACs have unusual A-type linkages compared to the more
common B-type linkages found in PACs from other tannin-rich foods (Foo et al.,
2000; Howell et al., 2005). There are no existing data about the anti-adherent
effect of B-linkage proanthocyanidins against pathogenic microorganism.
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Cranberry PACs consists of epicatechin unids (epicatechin-(4β-8, 2β-O-7)epicatechin-(4β-8)) (Duarte et al., 2006) with degree of polymerization (DP) of 4
and 5 and at least one A-type linkage (Seeram et al., 2004). The mode of action
of the cranberry type-A PACs is still unknown, however, it has been suggested
they

act

by

hydrophobic

interactions,

which

modify

bacterial

surface

macromolecules like fimbria and lipopolysaccharides (Steinberg et al., 2005),
reducing adherence to epithelial cells.
Steinberg et al., 2005 observed anti-adherence and anti-biofilm formation
activity against Streptococcus sobrinus by cranberry high molecular weight
component (15000 MW cutoff) also known as nondialyzable material (NDM).
Another study reported that cranberry juice inhibited the adherence of
Helicobacter pylori to human gastric mucus and to human erythrocytes (Burger et
al., 2000).
Campylobacter jejuni and Campylobacter coli are among the leading
human foodborne pathogens (Leblanc-Maridor et al., 2011) and have been
implicated as the most common cause of gastroenteritis in developed countries.
The consumption of chicken contaminated with Campylobacter is considered a
major risk factor for human infection (Friedman et al., 2000). Although
Campylobacter infections have low mortality, about 76 people die each year from
Campylobacter infections (CDC, 2013). In addition to causing gastroenteritis,
Guillain-Barré

syndrome

(GBS)

is

the

most

significant

implication

of

Campylobacter jejuni infections (Buzby et al., 1997; Mawla et al., 2014). It is a
rare autoimmune disease that affects the peripheral nervous system causing
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muscle weakness and paralyses. Around 40% of the cases of GBS in United
States are due to previous campylobacteriosis (Buzby et al., 1997; CDC, 2013).
It is estimated that approximately one every 1,000 cases of reported
Campylobacter illness leads to GBS (CDC, 2013).
The mechanisms of pathogenesis for Campylobacter are not well
understood. However, adherence to host epithelial cell is the first and perhaps
the most important step for bacterial colonization and infection. Thus, there is a
considerable

interest

in

identifying

Campylobacter infection in humans.

preventive

strategies

to

mitigate

One approach would be to reduce

colonization of this organism in poultry, and the anti-adherence approach using
non-digestible oligosaccharides and naturally derived molecules could be a
potential solution. MOS, in particular, have been suggested to be effective antiadherence agents.
Although anti-adherence strategies have been proposed for several
human and animal applications, this approach has one important limitation.
Specifically, it is known that pathogenic bacteria often encode and express genes
for more than one type of adhesin, a process known a phase variation
(Henderson et al., 1999). Hence, it may be more effective to target more than
one adhesion, by using a mixture of different anti-adherence agents to provide a
broad spectrum effect (Ofek et al., 2003; Shoaf & Hutkins, 2009).
The main goal of this research was to assess the ability of both mannan
oligosaccharides

whole

soluble

fraction

(MOS),

purified

mannan

oligosaccharides (pMOS), cranberry high molecular weight component (HMW)

!

!

69!

and the combination of MOS and HMW to inhibit adherence of C. jejuni and C.
coli to HEp-2 tissue culture cells.
Materials and Methods
Organisms and growth conditions. Strains of C. jejuni subsp. jejuni ATCC
29428, C. jejuni subsp. jejuni ATCC 700819, C. jejuni subsp. jejuni ATCC 33291,
C. coli ATCC 43485 and C. coli ATCC BAA-1061 were obtained from W. Miller
(Agricultural Research Service, Albany, CA) and used for all the adherence
experiments. Prior to each experiment, frozen stock cultures of each organism
were thawed, plated onto Columbia Blood Agar Base (Oxoid) with 7% of horse
blood defibrinated (BBLTM) and grown for 48 hours at 42°C in modular incubator
chamber under microaerophilic environment (5% O2, 10% CO2, and 85% N). A
single colony was inoculated into 10 ml of Brucella Broth (BBLTM; BD)
supplemented with 250 µL of Fetal Bovine Serum defined (FBS; HyClone®) and
grown in semi-solid media using the biphasic system (5 mL of Brucella agar and
10 mL of Brucella broth in sterile 25 cm2 C/N tissue culture flasks (Corning) in
horizontal position) and incubated under microaerophilic environment at 42°C
during 24 hours (late exponential phase). After 24 hours incubation, cultures
were harvested by centrifugation (4000 x g for 8 minutes). The cells were
washed twice with Phosphate-Buffered Saline (PBS) pH 7.4 and re-suspended in
Minimal Essential Medium (MEM/EBSS, HyClone, Thermo Fisher Scientific Inc,
Utah, USA) supplemented with 10% fetal bovine serum (FBS; HyClone®). MEM
was pre-equilibrated overnight at tissue culture conditions (5% CO2, 95% relative
humidity at 37°C).
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Yeast mannan oligosaccharides (MOS). Yeast mannan oligosaccharide was
obtained from Lallemand (Ontario, Canada) as a powdered material. According
to the supplier, the starting material contained 24% MOS and 25% β-glucan. To
fractionate this material, a stock solution was prepared dissolving 100 mg of
powder per mL of distilled water. The solution was centrifuged at 1000 x g for 10
minutes to remove insoluble material. The soluble supernatant fraction was
collected, filtered through a 0.4-µm filter, and freeze dried. A stock solution was
prepared in distilled water at a final concentration of 100 mg/ml (pH 7.0).
To separate the mannan oligosaccharides from the β-glucan, the stock solution
was mixed with 100% ethanol at a ratio of 3:1. After 1 hour, two phases were
observed, allowing for separation. The precipitated β-glucan was freeze dried,
and the supernatant containing the MOS was collected and the ethanol was
removing using a rotary evaporator. The final component was then freeze dried.

Cranberry extract. Cranberry concentrate was obtained from Ocean Spray
Cranberries, Inc (Lakeville-Middleboro, MA). The concentrate was also
fractionated by dialysis to yield a high molecular weight component (HMW).
Briefly, approximately 50 mL of concentrate was dispensed into dialysis tubing
(12,000 – 14,000 MW cutoff). The material was dialyzed for 4 days at 4°C
against distilled water with agitation. The non-dialyzable material was then freeze
dried. A stock solution was prepared by resuspending the freeze-dried material in
distilled water to a concentration of 10 mg/ml (pH 7.0). The solution was filter
sterilized using 0.45 µm filters and stored at -20°C.

!

!

71!

Tissue culture cells. HEp-2 cells were obtained from the American Type Culture
Collection (ATCC; Manassas, Virginia). Cells were grown in 150 cm2 sterile tissue
culture flasks (Corning) containing 50 mL of MEM with 10% Fetal Bovine Serum
(FBS) and incubated (5% CO2, 95% relative humidity at 37°C). Confluent HEp-2
cells were washed once with PBS (pH 7.4) and harvested by adding 3.5 ml of
Trypsin-EDTA Solution (Sigma) and incubating for 10 minutes at tissue culture
conditions. Then, trypsin was inactivated with 3.5 ml of FBS. After that, cells were
seeded onto 12-mm diameter wells in 24-well tissue culture plates (Thermo
Scientific) at approximately 3.6 x 105 viable cells per well, and 500 µL of Minimal
Essential Media (MEM) supplemented with 10% FBS was added to each well.
Plates were incubated under tissue culture conditions for one day prior to the
start of each experiment.

Adherence assays. Cells suspension of C. jejuni and C. coli were prepared as
described above. The MOS, pMOS, or HMW were mixed with bacterial cultures
(in MEM supplemented with 10% FBS and pre-incubated for 1 hour in
microaerophilic conditions at 42°C) prior to being added to the tissue culture
cells. As a control, water was added to the bacterial cultures at the same volume
as the agent. The plates were incubated for 3 hours at tissue culture conditions.
The wells were then washed 5 times with PBS (pH 7.4) to remove non-adhered
bacterial cells. Experiments were replicated 6 times (n = 6) for analysis by
quantitative plating. Adherence was also observed microscopically (Quintero et
al., 2011)
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For other experiments, MOS and HMW were prepared as concentrated stock
solutions with distilled water at a final concentration of 100 mg/mL and 10
mg/mL. A 1:1 blend of MOS and HMW was prepared by mixing equal volumes to
give a 50 mg/mL and 5 mg/mL of each one respectively. A negative control was
prepared with distilled water and a positive control was made with the
combination of distilled water and the component at the same concentration of
the blend. The solutions were filter sterilized using 0.45-µm.

Invasion assays. The same procedure described above was followed for cell
infection. Cell monolayers were washed 5 times with PBS (pH 7.4), and then 250
µL of pre-equilibrated MEM (supplemented with 10% FBS) with 150 µg/mL of
gentamycin sulphate (Sigma) and 250 µL of 100 mg/mL of MOS were added.
Cell monolayers were incubated 2 hours at 37°C in a 5% CO2 humidified
atmosphere chamber. Monolayer cells were then lysed with 1 mL Triton X-100 at
1% v/v in PBS (pH 7.4). Invaded bacteria were determined by serial dilutions and
cultured on plates of Brucella Agar (BBLTM; BD). The minimum inhibitory
concentration (MIC) of each agent needed to inhibit the invasion of C. jejuni and
C. coli to HEp-2 tissue cell lines were expressed as the percentage of invasive
bacterial relative to an invasion control.

Culture Enumeration: Cells were washed as described above and detached by
addition of 0.1% Triton X-100 in PBS and repeated pipetting. The cells were
collected and enumerated on Brucella Agar (BBLTM; BD) after incubating at 42°C
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for 48 hours in microaerophilic conditions. Adherence inhibition was calculated as
the average number of adhered bacteria per ml in the control minus the average
number of adhered bacteria per ml in the treatment divided by the number of
adhered bacteria per ml in the control.

PCR screening for adhesin identification:
Campylobacter strains were growth as described above. Cells were harvested
from Brucella broth after 24 hours of incubation and DNA was extracted using
DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany). Instructions provided
in the manufacturer’s manual for DNA extraction were followed for Gram
negative bacteria.
An internal fragment of each gene was amplified via PCR using the primers listed
in Table 1. Genes were amplified using the following parameters: 94°C for 2 min
(1 cycle): 94°C for 45 s, 60°C (-1° per cycle) for 30 s, 70° for 1.5 min (10 cycles);
94°C for 45 s, 50°C for 30 s, and 70°C for 1.5 min (25 cycles); and 70°C for 1.5
min (25 cycles); and 70°C for 8 min (1 cycle) (Flanagan et al., 2009). PCR
amplified products (8 µL) were resolved in 1.0% agarose gel ( 60 V, 90 min) and
visualized by staining with ethidium bromide.
Table 1. Specific primers used in this study to identify presence of suspected
adhesin genes.
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Locus tag

Gene
product

Primer*

Sequence

TATTTCTATGGTTTAGCAGGTGGAG
cadF-F
Cj1478c
CadF
(cadF)
GCTCTACCTTCTTTAGTGTCATTGC
cadF-R
TGAATCGAAGTGGAAAAATAGAAG
capA-F
Cj0628
CapA
(capA)
CCCATTTTTGTATCTTCATAACCT
capA-R
TCTCAGGACTCTGGAATAAAGATTG
jlpA-F
Cj10983
JlpA
(JlpAF)
GTGTGCTATAGTCACTAACAGGGATG
jlpA-R
Cj1279c
Cj1279c Cj1279c-F TCAGAAGATGGCAAGGTTATAGAAG
(cadF)
(FlpA)
Cj1979c-R GTTATTGCTATTGATTCAGCTGGAC
TCTAGGTGCTTGTGTTGCATTTAG
peb1-F
Cj0921c
PEB1
(peb1A)
peb1-R
TGTCTACAGAAAACGCATCAACTC
* Primer used to amplify a DNA fragment for the present/absent identification of
specific adhesin gene.

Statistical analysis:

Significant differences between the treatments was

determined by analysis of variance (ANOVA) and Tukey’s test to compare all
pairs of columns were used to determine differences between the different
concentrations. GraphPad Prism 5 Software (Version 5.03) was used for the
statistical analysis.

Results
Mannan oligosaccharides reduce adherence of Campylobacter jejuni and
Campylobacter coli to HEp-2 cells. Adherence assays with all strains of C. jejuni
and C. coli were conducted in the presence and absence of MOS. Bacteria
adherence to HEp-2 cells was measured by cultural enumeration (Figure 1). The
results showed that high concentration of MOS (up to 40 mg/ml) were necessary
to achieve an anti-adherence effect of the strains used for these studies. Thus,
40 mg/mL and 50 mg/mL inhibited adherence of C. jejuni ATCC 29428 by 94%
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and 94%, C. jejuni ATCC 700819 by 73% and 94%, C. jejuni ATCC 33291 by
71% and 82%, and C. coli ATCC 43485 by 91% and 92%, respectively.
However, there was no significant effect on the adherence of C. coli ATCC BAA1061, suggesting that the effect found in MOS may be Campylobacter strainspecific. Microscopic observations provided qualitative evidence of the antiadherence activities of the MOS (Figure 2).

Adherence of C. jejuni and C. coli in the presence and absence of purified MOS
gave similar results as for the whole soluble MOS (Figure 3). Experiments
revealed that the minimum inhibitory concentration of the purified MOS was also
40 mg/mL and that adherence of C. coli ATCC BAA-1061, was not affected by
MOS at any of the concentrations.

Mannan oligosaccharides does not reduce invasion of Campylobacter jejuni
and Campylobacter coli to HEp-2 cells. Invasion assays were conducted for all
five strains of Campylobacter on HEp-2 cells. Invasion was measured by cultural
enumeration. The results revealed that there were no significant reductions in the
invasion of C. jejuni ATCC 700819, C. jejuni ATCC 33291, C. jejuni ATCC
29428, C. coli ATCC 43485 and C. coli ATCC BAA-1061 in presence of MOS (50
mg/mL) (data not shown).

High Molecular weight of cranberry extract reduces adherence of
Campylobacter jejuni and Campylobacter coli to HEp-2 cells. Adherence assays
with all five strains of C. jejuni and C. coli were conducted in the presence and
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absence of cranberry HMW component to HEp-2 cells. Adherence was
measured by cultural enumeration (Figure 4). The results revealed that the
adherence of C. jejuni strains was inhibited by greater than 90% at the highest
concentration of 5 mg/mL of HMW. However, the minimum concentration to
achieve more than 50% of inhibition for four of five of the strains tested was 3
mg/mL. There was no significant effect in the adherence of C. coli ATCC BAA1061.

High Molecular weight of cranberry extract does not reduce invasion of
Campylobacter jejuni and Campylobacter coli to HEp-2 cells. Invasion assays of
C. jejuni and C. coli in presence and absence of cranberry HMW component
were measured by numerical enumeration (data no shown). The results revealed
that there was no effect in the invasion process in presence of the highest dose 5
mg/mL of HMW with all the strains tested in this study.

Combinations of MOS and HMW are not additive. Adherence assays with all
five strains of C. jejuni and C. coli were conducted in the presence and absence
of a blend (1:1) of cranberry HMW and MOS. Bacteria adherence to HEp-2 cells
was measured by cultural enumeration (Figure 5). Although, both HMW and
MOS were effective at reducing adherence of C. jejuni ATCC 700819, C. jejuni
ATCC 33291 and C. jejuni ATCC 29428 to HEp-2 cells, the results revealed that
there was not additive effect of the blend HMW/MOS. That is, the extent of the
inhibition was neither additive nor augmented by the mixture of the HMW/MOS.

!

!

77!
Results with C. coli ATCC 43485 showed as before that MOS is effective

against the adherence to HEp-2 cells, but HMW was not.

There was no

significant effect on the adherence of C. coli ATCC BAA-1061, suggesting that
the effect found in MOS and HMW may be Campylobacter strain-specific.

Campylobacter jejuni expresses all of the adhesins screened in this study.
PCR was conducted to amplify adhesin genes using specific primers (Table 2).
All C. jejuni strains were positive for the presence of all five adhesins tested in
this study. However, only two adhesin genes were identified for C. coli strains.

Table 2. Presence/Absence of adhesin genes for the Campylobacter strains used
in this study.

Strains
C. coli ATCC BAA-1061
C. coli ATCC 43485
C. jejuni ATCC 700819
C. jejuni ATCC 33291
C. jejuni ATCC 29428
(+ Presence / - Absence)

cadF
+
+
+
+
+

Target Adhesin genes
peb1A
jlpA
capA
+
+
+
+
+
+
+
+
+
+
+

Cj1279
+
+
+

Discussion
Over the past several years, different beneficial effects have been
attributed to MOS (Davis et al., 2002; Ferket et al., 2005; Hanning et al., 2009;
Staykov et al., 2007). Because they are also easy to produce at a relatively low
cost, MOS have gained significant interest in agricultural applications. In
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particular, MOS have been widely used in animal production as a feed
supplement to replace antibiotics and other growth promoting agents (Baurhoo et
al., 2009; Castillo et al., 2008). Most studies have been conducted in-vivo with
broiler chicks, pigs, and fish and less extended in cattle and pets. In these
reports, the population of pathogenic bacteria such as Salmonella, E. coli,
Campylobacter and Clostridium was reduced after supplementation with MOS in
the animal diet. Additionally, MOS have been shown to enhance growth
performance of livestock animals.
Cranberry is a widely consumed fruit in United States and it has been
identified to have a diverse biological properties (Duarte et al., 2006; Ofek et al.,
1991; Sobota, 1984), among them the ability to inhibit the adherence and biofilm
formation of some pathogens to epithelial cells (Burger et al., 2000; Foo et al.,
2000; Zafriri et al., 1989). A high molecular weight component isolated from
cranberry has been found to present the anti-adherent capacity (Burger et al.,
2000), acting as inhibitor or by altering bacterial surface hydrophobicity
(Steinberg et al., 2005)
In this study, adherence inhibition of three strains of C. jejuni and two
strains of C. coli to HEp-2 cells in the presence of MOS, pMOS, cranberry HMW
and a blend of MOS/HMW was determined. The results showed that both
fractions MOS and pMOS at 40 mg/ml and 50 mg/mL have the property to inhibit
adherence of some strains of Campylobacter. However, there were no significant
differences between the whole soluble mannan oligosaccharide and purified
fractions. This suggests that the anti-adherence effect is due to the mannan
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oligosaccharides fraction and that the β-glucan fraction does not inhibit
adherence. The mannan oligosaccharides material used in this study is derived
from yeast cell walls produced from S. cerevisiae and was composed mainly by
mannan oligosaccharides, β-glucan and others unknown ingredients. However,
the exact amount of mannan oligosaccharides in both fractions (MOS and
pMOS) is unknown. Efforts to understanding and identifing the mode of action of
each of the commercial MOS compounds is worthy of exploration.
Results shown that the adherence of C. jejuni strains and C. coli ATCC
43485 was significantly reduced by cranberry HMW at a minimum concentration
of 2 mg/mL and 3 mg/mL, respectively. However, at higher concentrations (up to
5 mg/mL) further reductions in adherence were not observed. Adherence of C.
coli ATCC BAA-1061 was not inhibited by any dose of HMW.
The results with the blend of MOS/HMW showed that there was not an
additive effect with these components. This suggests that some of the strains
used in this study express a particular adhesin that is target for both MOS and
HMW, or one of the anti-adhesive agents have a broad spectrum to target
different Campylobacter adhesins.
Although the adherence mechanisms of Campylobacter are not well
understood, several adhesins have been described. Importantly, adherence to
host epithelial cells appears to be crucial for C. jejuni colonization of chickens
(Flanagan et al., 2009; Ziprin et al., 1999). Adhesins as CadF (Campylobacter
adhesin to fibronection) are involved in the adherence of C. jejuni to fibronection
(Konkel et al., 1999). Previous studies have suggested that CadF promotes
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adherence in cell culture systems and during chicken colonization (Mourik, 2011:
Flanagan, 2009; Konkel et al, 1997). Moreover, C. jejuni cadF mutants were
shown to have reduced adherence (50%) to intestinal human cells compared
with the C. jejuni wild-type strain (Flanagan et al., 2009; Monteville, Yoon, &
Konkel, 2003). Two other major outer membrane proteins, CapA (Campylobacter
adhesin protein A) and JIlpA (Campylobacter jejuni surface lipoprotein A) have
been identified and suggested to mediate adherence of the bacterium to
epithelial cells (Flanagan et al., 2009; Jin, Song et al., 2003). However, Flanagan
et al, (2009) reported that CapA is not conserved among the strains of C. jejuni
tested in the study, suggesting this adhesin may not be essential for
Campylobacter colonization in chickens. Nevertheless, this particular protein may
contribute during the initial steps of the adherence process. Jin et al, (2003)
reported that JlpA is a surface exposed lipoprotein that is crucial for HEp-2 cell
binding. Previous work has suggested that JlpA is located predominately in the
bacterial inner membrane and can be found loosely associated with the outer
membrane (Flanagan et al, 2009). PEP1 is a periplasmic binding protein
associated with ABC transports (ATP-binding cassette (ABC) transports).
Disruption of peb1A has been shown to reduce C. jejuni adherence to human
HeLa epithelial cells (Kervella et al, 1993), and C. jejuni mutant strains failed to
colonize the intestinal tract of mice (Pei et al, 1998). There are still open
questions to be resolved about Campylobacter pathogenesis. In particular, it will
be necessary to understand the importance and contribution of each known
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adhesin for colonization, and additionally to identify the specific receptors for
these adhesins.
There are few in vitro studies that have compared MOS preparations in an
anti-adherence

model.

Previously,

in

vitro

analysis

with

yeast-derived

mannoproteins suggested that the yeast cell wall is effective at inhibiting
adherence of C. jejuni to Caco-2 cells, but it had no significant effect on invasion
(Ganan et al., 2009). Mannose derived from Candida albicans cell walls was
shown by Oyofo et al., (1989) to inhibit the in vitro adherence of Salmonella
typhimurium to intestinal cells of day old chickens. Another study reported that
mannose was effective at blocking adherence of C. jejuni on Caco-2 cells by
(Russell & Blake, 1994). These results indicated that the mannose content in the
mannoprotein fraction appeared to be crucial for inhibiting the adherence process
of some pathogenic microorganisms.
Mannose is a component of N-glycan structures (Parry et al., 2006), and
many pathogens bacteria bind to mannose residues on the host tissue. Most of
the mannose-binding lectins that have been identified in bacteria contain FimHlike adhesins commonly located at the tip of type I fimbriae (Firon et al., 1984;
Ganner & Schatzmayr, 2012). However, these extracellular adhesins have not
been recognized in C. jejuni. In contrast, E. coli and Salmonella are known to
possess these mannose-sensitive type 1 fimbriae (Day et al., 2009; Firon et al.,
1984; Neeser et al., 1986). In a previous study, Day et al. (2009) reported that C.
jejuni 11168-O has a mannose-binding lectic whose expression was dependent
on the environmental temperature and atmospheric conditons. Aditionally, Day et
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al. (2009) suggested that mannose recognition by C. jejuni may not require
mannose for initial adherence to host tissues, but may be unnecessary for
subsquent colonisation (Thomas et al., 2004; Thomas et al., 2002).
Finally, it was previously reported that C. jejuni does not ferment or
oxidase carbohydrates as a carbon source (Weingarten et al., 2009). Therefore,
any observed reduction of binding can be attributed to direct interactions involved
in adherence and not as an indirect metabolic effect (Day et al., 2009).
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Figure 1. Adherence of C. jejuni and C. coli to HEp-2 cells in the presence of
mannan oligosaccharides (0, 10, 20, 30, 40 and 50 mg/mL) analyzed by cultural
enumeration (n=6). Statistically significant effects are indicated by an asterisk.
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Figure 2. Microscopy observation 1000 x magnification of C. coli ATCC 43485
adhere to surface of HEp-2 cells. Control (A) and 50 mg/mL of MOS (B).

!

!

92!

A

B

!

!

93!

Figure 3. Adherence of C. jejuni and C. coli to HEp-2 cells in the presence of
purified mannan oligosaccharides (0, 10, 20, 30, 40 and 50 mg/mL) analyzed by
cultural enumeration (n=6). Statistically significant effects are indicated by an
asterisk.
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Figure 4. Adherence of C. jejuni and C. coli to HEp-2 cells in the presence of high
molecular weigh of cranberry extract (0, 1,2,3,4 and 5 mg/mL) analyzed by
cultural enumeration (n=6). Statistically significant effects are indicated by an
asterisk.
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Figure 5. Adherence of C. jejuni and C. coli to HEp-2 cells in the presence of high
molecular weight of cranberry extract and yeast mannan oligosaccharides (1:1,
HMW 5 mg/mL, MOS 50 mg/mL) analyzed by cultural enumeration (n=6).
Statistically significant effects are indicated by an asterisk, the letters significant
the differences among the treatments.
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Chapter 4
Adherence inhibition of Campylobacter jejuni and Campylobacter coli to HEp2 cells by pectin oligosaccharides
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Abstract
Many recent studies have described the beneficial effects and mechanisms of
action of prebiotics. However, there is now active interest in prebiotic
oligosaccharides derived from suitable bioresources. Pectic oligosaccharides
(POS) are non-digestible oligosaccharides commonly found in fruit and
vegetables. POS have been recognized for their potential prebiotic properties. In
addition to their ability to modulate the gut microbiota, POS have also been
suggested to inhibit attachment of some pathogens to epithelial cells. The goal of
this research was to assess the ability of orange pectic oligosaccharides to inhibit
the adherence of C. jejuni ATCC 29428, C. jejuni ATCC 33291, C. jejuni ATCC
700819, C. coli ATCC 43485 and C. coli ATCC BAA-1061. Adherence
experiments were performed using a human epithelial tissue cell line (HEp-2) in
the absence or presence of POS. There were no significant reductions in
adherence of any Campylobacter strains. However, adherence tended to
increase as the concentration of POS increases. The results obtained in this
work suggest that POS does not have an anti-adhesive effect on the specific
strains of C. jejuni and C. coli tested in this study. Further investigation is
necessary

to

determine

the

mechanisms

of

interaction

of

POS

and

Campylobacter strains in an in vitro model.

Introduction
Prebiotics are defined as non-digestible food ingredients that beneficially
affect the host by selectively stimulating the growth and/or activity of one or
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limited number of bacterial species in the colon (Gibson et al., 1995). The
commercial prebiotic products currently on the market are produced by
enzymatic synthesis or degradation of materials such as lactose, sucrose, inulin,
starch and xylan (Hotchkiss et al., 2003; Crittenden & Playner, 1996).
Non-digestible oligosaccharides (NDO) have been suggested as potential
agents for improving gut health and well-being by maintaining a balanced
intestinal microbiota (Roberfroid, 2007). Recently, some NDO have been
recognized to have other biological properties. Specifically, they may block the
adherence of some pathogenic bacteria, preventing these pathogens from
attaching to target cells in the gut (Shoaf et al., 2006). Since adherence is the
first and more important step in bacteria pathogenesis (Savage, 1977; Shoaf &
Hutkins, 2009), strategies based adherence inhibition could be very effective.
NDOs are among the agents being considered for this function (Klemm et al.,
2010; Shoaf et al., 2006). Specifically, pectic oligosaccharides (POS) have been
proposed to have this activity (Paeschke & Aimutis, 2011).
Pectin is an acidic polysaccharide found in fruit and vegetable processing
residues (Poli et al., 2011). Pectin consists of homogalacturonan and
rhamnogalacturonan I (RGI) in the backbone with arabinan, galactan and
arabinogalactan neutral sugar-chains attached to rhamnose in RGI regions
(Carpita & Gibeaut, 1993; Holck et al., 2014; Ridley et al., 2001). POS are
complex polysaccharides that represent one of the major components of plant
cell wall of dicotyledonous plants (Mandalari et al., 2006; Willats et al., 2000).
POS are formed via enzymatic hydrolysis of pectins (DP 2-20) (Holck et al.,
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2014), resulting mainly in monomers of α-1-4-linked galactosyluronic acid
residues (Alonso & Parajo, 2010).
Pectin-derived oligosaccharides from plant cell walls are produced by
several chemical and physical steps. The cell wall material is pre-treated and the
pectin polysaccharides are extracted. The oligosaccharides are released and
separated and then purified by chromatography (Holck et al., 2014). Commercial
pectin for food additive purposes depends of molecular weight, degree of
esterification and intrinsic viscosity (Hotchkiss et al., 2003).
POS have been proposed to be a potential prebiotic (Ganan et al., 2010).
POS have been evaluated to stimulate the growth of beneficial bacteria, including
Lactobacillus (Mandalari et al., 2006b) and Bifidobacterium (Manderson et al.,
2005; Olano-Martin et al., 2002). In addition to their putative prebiotic activity,
POS have also been recognized for their ability to inhibit the adherence of
pathogens (Hotchkiss et al., 2003; Holck et al., 2014).
The main goal of this research, therefore, was to asses the ability of pectic
oligosaccharides (POS) to inhibit the adherence of C. jejuni and C. coli in HEp-2
tissue culture cells..
Materials and Methods
Organisms and growth conditions. Strains of C. jejuni subsp. jejuni ATCC
29428, C. jejuni subsp. jejuni ATCC 700819, C. jejuni subsp. jejuni ATCC 33291,
C. coli ATCC 43485 and C. coli ATCC BAA-1061 were obtained from W. Miller
(Agricultural Research Service, Albany, CA) and used for all the adherence
experiments. Prior to each experiment, frozen stock cultures of each organism
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were thawed, plated onto Columbia Blood Agar Base (Oxoid) with 7% of Horse
Blood defibrinated (BBLTM) and grown for 48 hours at 42°C in modular incubator
chamber under microaerophilic environment (5% O2, 10% CO2, and 85% N). A
single colony was inoculated into 10 ml of Brucella Broth (BBLTM; BD)
supplemented with 250 µL of Fetal Bovine Serum (FBS; HyClone®) and grown in
semi-solid media using the biphasic system (5 mL of Brucella agar and 10 mL of
Brucella broth in sterile 25 cm2 C/N tissue culture flasks (Corning) in horizontal
position) and incubated under microaerophilic environment at 42°C during 24
hours (late exponential phase). After 24 hours incubation, cultures were
harvested by centrifugation (4000 x g for 8 minutes). The cells were washed
twice with Phosphate-Buffered Saline (PBS) pH 7.4 and re-suspended in Minimal
Essential Medium (MEM/EBSS, HyClone, Thermo Fisher Scientific Inc, Utah,
USA) supplemented with 10% fetal bovine serum (FBS; HyClone®). MEM was
pre-equilibrated overnight at tissue culture conditions (5% CO2, 95% relative
humidity at 37°C).

Orange pectic oligosaccharide (POS): Citric pectic oligosaccharide was
obtained from Agricultural Research Service Eastern Regional Research Center
(Wyndoor, PA), as a powdered material. A stock solution of 10 mg/ml was
prepared in phosphate buffer solution (PBS) at pH 7.4, filtered through a 0.45µm
filter and stored at -20°C.
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Tissue culture cells. HEp-2 cells were obtained from the American Type Culture
Collection (ATCC; Manassas, Virginia). Cells were grown in 150 cm2 sterile tissue
culture flasks (Corning) containing 50 mL of MEM with 10% Fetal Bovine Serum
(FBS) and incubated (5% CO2, 95% relative humidity at 37°C). Confluent HEp-2
cells were washed once with PBS (pH 7.4) and harvested by adding 3.5 ml of
Trypsin-EDTA Solution (Sigma) and incubating for 10 minutes at tissue culture
conditions. Then, trypsin was inactivated with 3.5 ml of FBS. After that, cells were
seeded onto 12-mm diameter wells in 24-well tissue culture plates (Thermo
Scientific) at approximately 3.6 x 105 viable cells per well, and 500 µL of Minimal
Essential Media (MEM) supplemented with 10% FBS was added to each well.
Plates were incubated under tissue culture conditions for one day prior to the
start of each experiment.

Adherence assays. Cells suspension of C. jejuni and C. coli were prepared as
described above.

The POS were mixed with bacterial cultures (in MEM

supplemented with 10% FBS and pre-incubated for 1 hour in microaerophilic
conditions at 42°C) prior to addition to the tissue culture cells. As a control, water
was added to the bacterial cultures at the same volume as the agent. The plates
were incubated for 3 hours at tissue culture conditions. The wells were then
washed 5 times with PBS (pH 7.4) to remove non-adhered bacterial cells.
Experiments were replicated 6 times (n = 6) for analysis by quantitative plating.
Adherence was also observed microscopically (Quintero et al., 2011).
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Invasion assays. The same procedure described above was followed for cell
infection. Cell monolayers were washed 5 times with PBS (pH 7.4), and then 250
µL of pre-equilibrated MEM (supplemented 10% FBS) with 150 µg/mL of
gentamycin sulphate (Sigma) and 250 µL of 10 mg/mL of POS were added. Cell
monolayers were incubated 2 hours at 37°C in a 5% CO2 humidified atmosphere
chamber. Monolayer cells were then lysed with 1 mL Triton X-100 at 1% v/v in
PBS (pH 7.4). Invaded bacteria were determined by serial dilutions and cultured
on plates of Brucella Agar (BBLTM; BD). The minimum inhibitory concentration
(MIC) of each agent needed to inhibit the invasion of C. jejuni and C. coli to HEp2 tissue cell lines were expressed as the percentage of invasive bacterial relative
to an invasion control.

Culture enumeration: Cells were washed as described above and detached by
addition of 0.1% Triton X-100 and repeated pipetting. The cells were collected
and enumerated on Brucella Agar (BBLTM; BD) after incubating at 42°C for 48
hours in microaerophilic conditions. Adherence inhibition was calculated as the
average number of adhered bacteria per ml in the control minus the average
number of adhered bacteria per ml in the treatment divided by the number of
adhered bacteria per ml in the control.

Statistical analysis:

Significant differences between the treatments were

determined by analysis of variance (ANOVA) and Tukey’s test to compare all
pairs of columns were used to determine differences between the different
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concentrations. GraphPad Prism 5 Software (Version 5.03) was used for the
statistical analysis.
Results
Pectic oligosaccharides do not reduce adherence of Campylobacter jejuni
and Campylobacter coli to HEp-2 cells. Adherence of C. jejuni and C. coli in
presence and absence of pectic oligosaccharides to HEp-2 cells was measured
by cultural enumeration (Figure 1). The results revealed that POS did not inhibit
the adherence of all five strains of Campylobacter tested in this study (Figure 2).
Interestingly, adherence tended to increase as the POS concentration increases.
We suggest that POS might function as a bridge to enhance binding of some
strains of Campylobacter to epithelial cells. However, C. jejuni ATCC 33291 was
the only strain that showed adherence reduction but it was not statistically
significant compared with the control.

Pectic oligosaccharides does not reduce invasion of Campylobacter jejuni
and Campylobacter coli to HEp-2 cells. Invasion assays of C. jejuni and C. coli
were conducted in presence and absence of POS by numerical enumeration
(Figure 3). The results revealed that there was no inhibitory effect on invasion in
the presence of the highest dose 5 mg/mL of POS of all the strains to HEp-2
cells.
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Discussion
The anti-adherence strategy against pathogens was proposed several
years ago (Andersson et al., 1986; Cravioto et al., 1991; Ofek & Beachey, 1978).
Since then, many studies have evaluated the activity of several oligosaccharides
that may act as molecular decoys and block the bacterial attachment to epithelial
cells. Prebiotic oligosaccharides are of considerable interest because, in addition
to their health promoting properties, they have been suggested to inhibit the
adherence of some pathogens and reduce bacterial colonization and infection.
Oligosaccharides from pectin (POS) are proposed to be in the group of potential
new generation of prebiotics (Paeschke & Aimutis, 2011).
In this report, we compared the ability of pectin oligosaccharides to inhibit
the adherence of C. jejuni and C. coli to HEp-2 cells. The results showed that
POS had no effect on adherence or the invasion of any of the Campylobacter
strains tested in this study. Adherence to HEp-2 was increased in some strains.
Pectic oligosaccharides are a co-product of pectin manufacturing. They
are a significant component of the supernatant remaining after pectin
precipitation (Ganan et al., 2010). Therefore, pectin is a suitable raw material for
the production of oligosaccharides with promising prebiotic potential (Alonso &
Parajo, 2010). The most common commercial sources of POS are citrus peel,
apple pomace, sugar beet pulp and potatoes pump (Holck et al., 2014).
Specially, orange pectin oligosaccharides were shown to prevent adhesion of
several E. coli strains, including E. coli NTCC 12900, E. coli NTCC 13127, E. coli
NTCC 13128, E.coli NTCC O111:H27, and Desulfovibrio desuldurincans.
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Adherence inhibition of over 80% of inhibition were reported (Rhoades et al.,
2008) and invasion of C. jejuni in Caco-2 cells (Ganan et al., 2010; Olano-Martin
et al., 2003). POS, have also shown protective effects against E. coli
verocytototixins in HT29 tissue culture cells (Olano-Martin et al., 2003; Paeschke
& Aimutis, 2011). Guggenbichler et al., 1997 reported that digalacturonic acid (αD-GalpA-(1-4)-D-GalpA) derived from acid pectin oligosaccharides inhibited
adherence of P-fimbriated E. coli to uroepithelial cells.
The methyl-esterified oligogalacturonic acids component in POS appear to
be responsible for the anti-adherent property and anti-toxin attachment to specific
epithelial receptors (Holck et al., 2014; Rhoades et al., 2008). However, it is clear
that the effect of POS may be strain specific.
Holck et al., 2014 reported that differences in POS sources and
composition could alter the results of bacterial adherence and invasion to specific
epithelial cells. Thus, a better understanding of the POS structure, function and
relationship with bacterial pathogens is required.
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Figure 1. Adherence of C. jejuni and C. coli to HEp-2 cells in the presence of
Pectic Oligosaccharide (0, 1, 2, 3, 4 and 5 mg/mL) analyzed by cultural
enumeration (n=6). An asterisk indicates statistically significant effects.
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Figure 2. Microscopy observation 1000 x magnification of C. coli ATCC 43485
adhere to surface of HEp-2 cells. Control (A) and 5 mg/mL of POS (B).
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Figure 3. Invasion of C. jejuni and C. coli to HEp-2 cells in the presence of POS 5
mg/mL) analyzed by cultural enumeration (n=6). Statistically significant effects
are indicated by an asterisk.
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Chapter 5
Conclusion
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In this research we proposed that mannan oligosaccharides and cranberry high
molecular weight components could be used to inhibit adherence of C. jejuni and
C. coli strains to epithelial cells. Specifically, we established that a mannan
oligosaccharides fraction was responsible for the anti-adherent effect against the
Campylobacter strains used in this studied. Furthermore, it was determined that
pectic oligosaccharides derived from orange did not inhibit the adherence of C.
jejuni and C. coli strains to epithelial cells. The major findings of this research are
described below.

•

MOS and pMOS effectively reduce adherence of C. jejuni and C. coli
strains in tissue culture experiments.

•

MOS are not effective at reducing the invasion of C. jejuni and C. coli
strains to epithelial cells.

•

The minimum MOS and pMOS concentration required for C. jejuni and C.
coli strains adherence inhibition was 40 mg/mL; higher concentrations did
not exhibit significantly higher adherence inhibition.

•

The activity of the effective MOS was attributed to the mannan fraction
and not to the β-glucan fraction.

•

Cranberry high molecular weigh component effectively reduce the
adherence of C. jejuni and C. coli strains in tissue culture experiments.

•

Cranberry high molecular weigh component is not effective for reducing
invasion of C. jejuni and C. coli strains to epithelial cells.
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•

The minimum HMW concentration required for inhibiting adherence of C.
jejuni and C. coli was 2 and 3 mg/mL, respectively; however, higher
concentrations did not enhance adherence inhibition.

•

There was no additive effect observed by using a combination of MOS
and HMW against adherence of C. jejuni and C. coli strains to epithelial
cells.

•

The anti-adherence effect of MOS and HMW was strain-specific.

•

Pectin oligosaccharides did not inhibit adherence or invasion of C. jejuni
and C. coli strains.

•

Collectively, the results obtained from this study provide evidence that
mannan oligosaccharides and cranberry extract have anti-adherence
activity and may be useful act as prophylactic agents against pathogenic
bacteria that infect production animals.
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